JP2011520969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520969A5 JP2011520969A5 JP2011510614A JP2011510614A JP2011520969A5 JP 2011520969 A5 JP2011520969 A5 JP 2011520969A5 JP 2011510614 A JP2011510614 A JP 2011510614A JP 2011510614 A JP2011510614 A JP 2011510614A JP 2011520969 A5 JP2011520969 A5 JP 2011520969A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- aryl
- haloalkyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 43
- 150000003839 salts Chemical class 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 31
- 229940002612 prodrug Drugs 0.000 claims description 30
- 239000000651 prodrug Substances 0.000 claims description 30
- 239000012453 solvate Substances 0.000 claims description 30
- 125000001188 haloalkyl group Chemical group 0.000 claims description 28
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 28
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000000883 anti-obesity agent Substances 0.000 claims description 10
- 229940125710 antiobesity agent Drugs 0.000 claims description 10
- 239000000556 agonist Substances 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- -1 —O-alkyl Chemical group 0.000 claims description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000003472 antidiabetic agent Substances 0.000 claims description 6
- 229940125708 antidiabetic agent Drugs 0.000 claims description 6
- 229940124802 CB1 antagonist Drugs 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 4
- 108090001061 Insulin Proteins 0.000 claims description 4
- 102000016267 Leptin Human genes 0.000 claims description 4
- 108010092277 Leptin Proteins 0.000 claims description 4
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 claims description 4
- 101710151321 Melanostatin Proteins 0.000 claims description 4
- 102400000064 Neuropeptide Y Human genes 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000003623 enhancer Substances 0.000 claims description 4
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims description 4
- 229940125396 insulin Drugs 0.000 claims description 4
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 4
- 229940039781 leptin Drugs 0.000 claims description 4
- 102000006953 melanin-concentrating hormone receptor activity proteins Human genes 0.000 claims description 4
- 230000037323 metabolic rate Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 claims description 4
- 235000015816 nutrient absorption Nutrition 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 239000002469 receptor inverse agonist Substances 0.000 claims description 4
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 4
- 230000003178 anti-diabetic effect Effects 0.000 claims description 3
- 229940123455 Beta glucosidase inhibitor Drugs 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 2
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000036772 blood pressure Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000010276 construction Methods 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 230000004190 glucose uptake Effects 0.000 claims description 2
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 2
- 230000002440 hepatic effect Effects 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- 239000002830 appetite depressant Substances 0.000 claims 2
- 238000000034 method Methods 0.000 description 11
- 0 *C(*)N(C(*)=[N+]C1=C2C(*)=C(*)*=I1)C2=O Chemical compound *C(*)N(C(*)=[N+]C1=C2C(*)=C(*)*=I1)C2=O 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5431908P | 2008-05-19 | 2008-05-19 | |
| US61/054,319 | 2008-05-19 | ||
| PCT/US2009/044323 WO2009143049A1 (en) | 2008-05-19 | 2009-05-18 | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520969A JP2011520969A (ja) | 2011-07-21 |
| JP2011520969A5 true JP2011520969A5 (enExample) | 2012-07-05 |
Family
ID=41120129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011510614A Pending JP2011520969A (ja) | 2008-05-19 | 2009-05-18 | 二環式ヘテロ環誘導体およびｇｐｒ１１９モジュレーターとしてのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110065671A1 (enExample) |
| EP (1) | EP2297117B1 (enExample) |
| JP (1) | JP2011520969A (enExample) |
| AU (1) | AU2009249237A1 (enExample) |
| CA (1) | CA2724426A1 (enExample) |
| WO (1) | WO2009143049A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105124A1 (en) * | 2007-08-23 | 2009-04-23 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| WO2010009208A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| AU2012267556B9 (en) | 2011-06-09 | 2017-05-11 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of GPR-119 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1210825A1 (en) | 2012-07-11 | 2016-05-06 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| US9663475B2 (en) * | 2013-02-25 | 2017-05-30 | Merck Patent Gmbh | 2 amino-3,4-dihydrcquinazoline derivatives and the use thereof as cathepsin D inhibitors |
| CN104119231A (zh) * | 2013-04-27 | 2014-10-29 | 重庆华邦制药有限公司 | 二苯甲胺类化合物的制备方法及中间体 |
| CN103848794B (zh) * | 2014-04-01 | 2016-01-20 | 扬州大学 | 靛红酸酐及其衍生物的合成方法 |
| BR112016028404A2 (pt) | 2014-06-05 | 2018-07-03 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como pesticidas |
| JP6618530B2 (ja) | 2014-09-09 | 2019-12-11 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ｎ，２−ジアリールキノリン−４−カルボキサミドおよび抗炎症剤としてのその使用 |
| WO2016053855A1 (en) | 2014-09-29 | 2016-04-07 | The Scripps Research Institute | Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders |
| HK1255034A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| GB201514489D0 (en) | 2015-08-14 | 2015-09-30 | Bergen Teknologioverføring As | Hyperphenylalaninemia |
| WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| EP3658560A4 (en) | 2017-07-25 | 2021-01-06 | Crinetics Pharmaceuticals, Inc. | SOMATOSTAT IN MODULATORS AND USES THEREOF |
| CA3104760C (en) * | 2018-06-26 | 2023-09-26 | Kpc Pharmaceuticals, Inc. | Benzimidazole derivatives and use thereof as idh1 inhibitors |
| CA3188446A1 (en) * | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds |
| WO2021086957A1 (en) * | 2019-11-01 | 2021-05-06 | Fmc Corporation | An efficient new process for synthesis of 2-amino-5-chloro-n-,3-dimethylbenzamide |
| IL326872A (en) * | 2019-11-11 | 2026-04-01 | Dana Farber Cancer Inst Inc | EGFR allosteric inhibitors and methods of using them |
| CA3173731A1 (en) | 2020-02-28 | 2021-09-02 | Kallyope, Inc. | Gpr40 agonists |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
| CN116444445B (zh) * | 2023-04-20 | 2025-08-29 | 河北科技大学 | 一种喹唑啉酮类化合物及其制备方法 |
| US20260091048A1 (en) * | 2024-08-02 | 2026-04-02 | Eli Lilly And Company | Gip receptor agonist compounds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
| US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| WO1985005029A1 (en) | 1984-05-09 | 1985-11-21 | Medaphore Inc. | Oral insulin and a method of making the same |
| US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
| JPH05504969A (ja) * | 1990-02-13 | 1993-07-29 | メルク・エンド・カムパニー・インコーポレーテツド | 置換ベンジル要素を含有するアンギオテンシン２アンタゴニスト類 |
| US5264439A (en) * | 1990-02-13 | 1993-11-23 | Merck & Co., Inc. | Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element |
| US5642868A (en) | 1990-05-02 | 1997-07-01 | The United States Of America As Represented By The Secretary Of The Navy | Ceramic material |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| US5385894A (en) * | 1991-03-06 | 1995-01-31 | Merck & Co., Inc. | Disubstituted 6-aminoquinazolinones |
| US5401745A (en) * | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
| US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| JP3488890B2 (ja) * | 1993-11-09 | 2004-01-19 | アグロカネショウ株式会社 | ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤 |
| US5843866A (en) | 1994-12-30 | 1998-12-01 | Hampshire Chemical Corp. | Pesticidal compositions comprising solutions of polyurea and/or polyurethane |
| US5824638A (en) | 1995-05-22 | 1998-10-20 | Shire Laboratories, Inc. | Oral insulin delivery |
| US6153632A (en) | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
| ATE356113T1 (de) | 1997-05-14 | 2007-03-15 | Atherogenics Inc | Probucolbernsteinsäureester zur hemmung der expression von vcam-1 |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| DK1140184T3 (da) | 1998-12-23 | 2003-09-29 | Searle Llc | Kombinationer af cholesterylestertransferproteinhæmmere og nikotinsyrederivater til hjertekar indikationer |
| MXPA01006472A (es) | 1998-12-23 | 2004-03-10 | Searle Llc | Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares. |
| FR2802817B1 (fr) | 1999-12-23 | 2002-10-11 | Centre Nat Rech Scient | Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete |
| ATE348152T1 (de) | 2000-12-01 | 2007-01-15 | Astellas Pharma Inc | Verfahren zum screening von diabetes- heilverfahren |
| CN102558155A (zh) | 2003-01-14 | 2012-07-11 | 阿伦纳药品公司 | 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗 |
| WO2004076413A2 (en) | 2003-02-24 | 2004-09-10 | Arena Pharmaceuticals, Inc. | Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism |
| TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
| WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
| DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| US7723342B2 (en) | 2005-05-17 | 2010-05-25 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
| US7750015B2 (en) | 2005-05-17 | 2010-07-06 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| WO2007003486A1 (de) * | 2005-07-04 | 2007-01-11 | Boehringer Ingelheim International Gmbh | Verfahren zur herstellung von chinazolinonderivaten |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| KR20080091814A (ko) | 2006-01-20 | 2008-10-14 | 쉐링 코포레이션 | 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클 |
| NZ571869A (en) * | 2006-04-06 | 2011-11-25 | Prosidion Ltd | Heterocyclic GPCR agonists |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| CA2661371A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
| EP2148870A1 (en) * | 2007-04-20 | 2010-02-03 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
-
2009
- 2009-05-18 US US12/993,363 patent/US20110065671A1/en not_active Abandoned
- 2009-05-18 WO PCT/US2009/044323 patent/WO2009143049A1/en not_active Ceased
- 2009-05-18 JP JP2011510614A patent/JP2011520969A/ja active Pending
- 2009-05-18 AU AU2009249237A patent/AU2009249237A1/en not_active Abandoned
- 2009-05-18 EP EP09751278A patent/EP2297117B1/en not_active Not-in-force
- 2009-05-18 CA CA2724426A patent/CA2724426A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115244056A (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| US8901307B2 (en) | Chemical compounds 251 | |
| CA2758894C (en) | Novel thyroid hormone .beta. receptor agonist | |
| JP5462784B2 (ja) | Ｔｒｐｖ１アンタゴニストとその使用 | |
| KR101584826B1 (ko) | 스테아로일-ＣｏＡ 데새투라제의 헤테로시클릭 억제제 | |
| ES2327684T3 (es) | Compuestos heteroaril-tetrahidropiridilo utiles para el tratamiento o la prevencion del dolor. | |
| JP2011515341A5 (enExample) | ||
| JP2011529964A5 (enExample) | ||
| JP2010506854A5 (enExample) | ||
| JP2020526561A5 (enExample) | ||
| JP2017538773A5 (enExample) | ||
| JP2011507878A5 (enExample) | ||
| CA2463284A1 (en) | Pyrimidine compounds and pharmaceutical compositions containing the compounds | |
| CA2375810A1 (en) | Beta2-adrenoceptor agonists | |
| JP2009500347A5 (enExample) | ||
| JP2022548250A5 (enExample) | ||
| JP2007502295A5 (enExample) | ||
| JPH0283384A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| US12012381B2 (en) | Dimethyltryptamine analogues as nitric oxide delivery drugs | |
| US20100130499A1 (en) | Bicycloheteroaryl compounds and their use as trpv1 ligands | |
| CA2796877A1 (en) | Novel beta 3 adrenergic receptor agonists | |
| DE102006009813A1 (de) | Verwendung von A2b/A1 Rezeptor Agonisten zur Modulation der Lipidspiegel | |
| JP5876423B2 (ja) | Ｔｒｐｖ１阻害活性を有する化合物とその使用 | |
| TW202102474A (zh) | 吡咯化合物 | |
| RU2010113358A (ru) | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов |